Research Actitivy
Our research focus is clear: advance the science of cognitive decline prevention and care — responsibly, transparently, and with respect for the people who participate.
Why we do research
When memory and cognition begin to change, people deserve more than uncertainty. That’s why Rezilir Health supports research: to help clarify what’s contributing to cognitive decline, and to strengthen the evidence behind precision, personalized approaches.
Not everyone who needs answers can sit in an exam room with us. Research is one way we can contribute to progress that reaches farther — by sharing what we’re learning through IRB-approved studies, safety monitoring programs, registries, and peer-reviewed publications.
Precision Medicine
We have been working on precision medicine since 2018, when Rezilir Health launched its precision medicine program and members of our clinical team co-authored a publication describing 100 cases of cognitive decline managed using a personalized, biomarker-guided approach.
In 2021, an important pilot study helped strengthen the scientific foundation for precision medicine approaches in cognitive outcomes. The study reported a highly clinically significant improvement overall: 84% of participants improved their Neurocognitive Index on CNS Vital Signs, with an average 10-point gain on the standard score (for context, 15 points reflects one standard deviation of change).
Since 2023, our primary research focus has been the IRB-approved Evanthea Trial , where we serve as a principal investigator site studying outcomes in individuals with mild cognitive impairment using a structured precision medicine protocol.
Evanthea Trial
Rezilir Health served as a principal investigator site in the IRB-approved Evanthea Trial, a randomized, multicenter, controlled study evaluating a personalized precision medicine approach in individuals with mild cognitive impairment and early dementia.
The trial enrolled 72 participants across six centers — Miami, FL; Cleveland, OH; Marin, CA; Walnut Creek, CA; Nashville, TN; and Sacramento, CA. Approximately two-thirds of participants received a personalized precision medicine regimen, while one-third received usual standard of care during the initial nine-month randomized phase.
- Lifestyle strategies addressing nutrition, sleep, exercise, stress reduction, and cognitive stimulation
- Targeted supplementation based on clinical findings
- Prescription therapies when indicated
- Neuromodulatory therapies as appropriate
The Evanthea Trial results have been published in pre-print form and are currently undergoing peer review. According to the pre-print, participants receiving personalized precision medicine demonstrated statistically significant improvements in certain cognitive measures compared to standard of care over the nine-month period. Results varied among individuals, and benefits were not uniform across all endpoints.
Rezilir enrolled 13 participants, all of whom completed the initial nine-month randomized phase as of August 2025.
Full interpretation of the findings will follow completion of the peer-review process.
Clinical Trial Disclosure
The intervention evaluated in the Evanthea Trial is not approved by the U.S. Food and Drug Administration for the treatment, cure, or prevention of Alzheimer’s disease, mild cognitive impairment, or dementia. The information provided here is for scientific and informational purposes only and is not intended as medical advice.
Precision Medicine Research Highlights
- 2018: Precision-medicine program launched; co-authored 100-case paper.
- 2021: Pilot study evaluating cognitive outcomes published.
- 2023: Became a principal investigator site for the Evanthea Trial.
- 2024–2025: Enrollment and care delivery across six centers.
- August 2025: Rezilir completed nine-month randomized phase for enrolled participants
- December 2025: Evanthea results released in pre-print form.
- Early 2026: Evanthea peer-review and neuromodulation methodology paper (targets).
Case Study on Cortical Basal Degeneration
Corticobasal syndrome (CBS) is a rare, progressive neurodegenerative condition that can affect movement, speech, and cognition — and it typically has limited treatment options beyond symptom management.
Rezilir Health contributed to a preprint case report describing the clinical course of an individual with CBS managed using a structured, precision-guided, integrative approach — reflecting the kind of multi-domain clinical thinking often required in complex, chronic cases.
The report documents substantial functional improvement. It is notable as an early, documented example suggesting that modifiable contributors, including toxic exposures and metabolic factors, may play a larger role in CBS symptom expression than previously recognized. These findings warrant further study.
A preprint version is available (Preprints.org; doi: 10.20944/preprints202508.2207.v1).
Read the preprint summary
Important context: This is a single case report. Case reports can inform future research questions, but they do not establish effectiveness or predict outcomes for other patients.
TB-006
Rezilir Health serves as an approved investigator site participating in real-world safety monitoring of TB006, a monoclonal antibody targeting galectin-3.
TB-006 is currently available under FDA compassionate use authorization for certain eligible patients with mild cognitive impairment or dementia who have not responded to other FDA-approved therapies.
All individuals receiving TB-006 must be enrolled in a formal safety monitoring program at an approved investigator site.
Rezilir Health does not make claims regarding specific outcomes related to TB-006 and adheres to all regulatory and safety oversight requirements.
Brain Health Registry
Rezilir Foundation, Inc. sponsors a registry of multimodal care for individuals with cognitive decline through the WCB Institutional Review Board (IRB Tracking ID: 20191727).
The purpose of this registry is to collect real-world data on precision medicine approaches in order to better understand clinical outcomes across diverse patient populations.
Participation in the registry is voluntary and conducted under IRB oversight.
Long Covid Registry
Rezilir Health participates in an IRB-approved registry led by researchers at the Institute of Neuro Immune Medicine at Nova Southeastern University.
The registry collects real-world data on precision medicine approaches in individuals experiencing persistent symptoms following COVID-19 infection.
Dr. Tanio serves as clinical faculty at the Institute, and Rezilir Health contributes clinical cases under IRB oversight.
Start Your Journey Today
Rezilir Health is a team of world-class clinicians and doctors practicing precision medicine at our Hollywood, Florida location.
Using an investigative approach we will work with you to get to the root cause of your chronic illness. We are an outcome-driven practice and believe that having a therapeutic relationship with our patients is critical. We focus on neurodegenerative disease, autoimmune disorders, dementia, and environmental-borne illnesses.
Rezilir Health treats patients from all over the world and is easily accessible from all major airports. Many offer direct flights into Ft. Lauderdale/ Hollywood (FLL), Miami (MIA), West Palm Beach (PBI), and the clinic is a relatively short drive from Boca Raton, Sarasota, Coral Springs and Jupiter.
Take the first step toward recovery
Start where you are and tell us what you are seeking. After you submit, a care coordinator from our team will reach out to confirm details and set up your next steps.
Cognitive Testing & Brain Health
Measure your baseline, find root causes, and build a plan for clarity.
Noticing changes in memory, focus, or word finding, or carrying a family risk? Our team measures where you are today, uncovers key drivers, and builds a plan for clearer thinking. Tap the button to return to the form; a care coordinator will contact you to schedule your evaluation.
Longevity & Healthy Aging
Track what matters and create a sustainable path to energy and resilience.
Ready to age well with energy, steadier sleep, and a sharper mind? Our team tracks the metrics that matter, then designs a sustainable plan that fits your life. Tap the button to return to the form; a care coordinator will contact you to set up your consult.
Precision Testing & Labs
Get the data you need and clear guidance on next steps.
Just need the data before you decide your next step? Our team coordinates epigenetic age, MRI volumetrics when appropriate, QEEG baselines, and comprehensive panels. Tap the button to return to the form; a care coordinator will contact you to explain results and options.
